Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Freshpet, Inc. due to allegations of materially misleading business information issued by the company [1] Company Summary - Freshpet, Inc. (NASDAQ: FRPT) is facing scrutiny regarding its business practices, which may have misled investors [1] - Shareholders who purchased Freshpet securities may be entitled to compensation through a contingency fee arrangement, meaning no out-of-pocket fees or costs for them [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fly-E Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Fly-E Group, Inc. securities is from July 15, 2025, to August 14, 2025, inclusive [1]. - Investors who purchased Fly-E securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [3]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Fly-E Group provided misleading statements regarding the safety of its lithium battery, which negatively impacted its E-vehicle sales revenue [4]. - Despite optimistic long-term projections, Fly-E's sales continued to decline, and operating expenses increased, leading to a failure in meeting revenue forecasts [4]. - The lawsuit claims that when the true information became public, investors suffered damages as a result [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2] - To serve as lead plaintiff, individuals must file a motion with the court by November 7, 2025 [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital [4] - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, resulting in investor damages when the true information became public [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on November 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in settlement numbers since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025, of the December 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 8, 2025, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Background - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper steroid usage, leading to investor damages when the truth was revealed [5].

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you currently own shares of Danaher stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=17717 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Why Rosen Law: We en ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of MoonLake Immunotherapeutics common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and statements [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that the defendants made false or misleading statements regarding the efficacy and clinical benefits of their product SLK compared to traditional monoclonal antibodies [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. - The Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. - A lead plaintiff must move the Court by December 15, 2025, to represent other class members in the litigation [1][3]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - No class has been certified yet, meaning investors are not represented unless they retain counsel [7]. - Investors can choose to remain absent from the class and still have the potential to share in any future recovery [7].

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The deadline to move the Court to serve as lead plaintiff is December 8, 2025 [3] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [4] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4] Group 3: Case Allegations - The lawsuit alleges that Cepton's defendants made materially false and misleading statements regarding the company's business and operations [5] - Specific allegations include failure to disclose a credible third-party bid valuing Cepton at more than double the Koito Acquisition and the Board's failure to explore this offer [5] - As a result, shareholders were deprived of the opportunity to consider the Koito Acquisition meaningfully [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased V.F. Corporation securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought V.F. Corporation securities between October 30, 2023, and May 20, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 12, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that V.F. Corporation's management made materially false and misleading statements regarding the company's turnaround plans, particularly concerning the Vans brand [5]. - It is claimed that the defendants concealed the need for additional significant reset actions to achieve growth for the Vans brand, which would negatively impact its revenue growth trajectory [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fluor Corporation securities between February 18, 2025, and July 31, 2025, about the upcoming lead plaintiff deadline on November 14, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Fluor securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that Fluor Corporation made false and misleading statements regarding the costs associated with several major projects, including the Gordie Howe International Bridge and various Texas highways [4] - It is claimed that these issues, along with reduced customer capital spending and economic uncertainty, negatively impacted Fluor's business and financial results [4] - The lawsuit asserts that Fluor's financial guidance for 2025 was unreliable, and the effectiveness of its risk mitigation strategies was overstated [4]